Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (89)	2/1/2000 10:10:00 AM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 107

News - Anthony Cerami, Ph.D to BOD Covalent Group, Inc. Appoints Distinguished Researcher to the Board Of Directors WAYNE, Pa., Feb. 1 /PRNewswire/ -- Covalent Group, Inc. (Nasdaq: CVGR) today announced that Anthony Cerami, Ph.D., a prominent, award-winning medical researcher, has been named to its Board of Directors. Dr. Cerami will assist the Company as it continues its growth into a major international clinical research provider. Dr. Cerami is a member of the National Academy of Sciences and the Institute of Medicine. Dr. Cerami has authored over 400 scientific publications and has been the inventor or co-inventor of more than 100 issued U.S. pharmacologic patents. In addition to his seat on numerous editorial boards, Dr. Cerami is currently Director of The Kenneth S. Warren Laboratories, Inc., a Visiting Research Professor at New York University, and President of Cerami Consulting Corp. Dr. Cerami, among his many honors and awards, was the 1999 recipient of the distinguished Banting Medal of the American Diabetes Association. Kenneth M. Borow, M.D., President and Chief Medical Officer of Covalent, said, "We enthusiastically welcome Dr. Cerami to our Board of Directors. He brings to the Company both an impressive network of pharmaceutical and biotechnology contacts and a distinguished research career in the fields of aging, immunology and diabetes. As a member of the Board of Directors, Dr. Cerami will be able to make an immediate impact as Covalent continues its impressive growth." Dr. Cerami said, "Dr. Borow and I have known each other for many years, and I am honored to have the opportunity to step onto Covalent's Board of Directors at such an exciting time in the Company's development. I am confident that my experience and contacts in the medical research as well as the pharmaceutical communities will be able to help Covalent as it expands further both in the United States and internationally." Covalent Group, Inc. provides drug development services and health management solutions to pharmaceutical, biotechnology, and device manufacturers as well as managed care organizations. To aid its customers, Covalent has developed several currently available proprietary products utilizing interactive speech recognition technology including TeleTrial(R), for use in clinical trials, and VirtualHouseCall(R), a disease assessment system. This document contains statements of a forward-looking nature.....